Introduction {#S1}
============

In 2015, mutation in *KCNA2* (MIM\#176262) was firstly identified as a novel cause of developmental and epileptic or epileptic encephalopathy ([@B19]). The *KCNA2* gene encoded the voltage-gate K^+^ channel K~V~1.2 that belonged to the K~V~1 family with eight members expressed in the central nervous system ([@B13]). Functional studies identified that pathogenic *KCNA2* mainly caused a dominant-negative loss-of-function and a drastic gain-of-function. Combined with the severity of the encephalopathy and the seizure disorder, the phenotype associated with *KCNA2* mutation could be differentiated into two main groups, the milder phenotype correlating with loss-of-function mutations and more severe phenotype with gain-of-function mutations ([@B19]). Subsequently, the phenotypic spectrum has been expanded up to include some forms of progressive myoclonus epilepsy or progressive ataxia, and myoclonic-atonic epilepsy ([@B16]; [@B4]; [@B20]).

Mosaicism was defined as the presence of different genotypic mutations among cells of an individual derived from a single zygote ([@B7]). Depending on the timing of mutation acquisition, mosaicism might be restricted to the germline mosaicism (also known as gonadal mosaicism), somatic mosaicism and gonosomal mosaicism (a combination of germline and somatic mosaicism) ([@B2]). The mosaicism arose due to postzygotic errors in DNA replication and could lead to disease state in the mosaic carriers or in the heterozygous offspring inheriting the mutant allele ([@B7]). The development and adoption of next-generation sequencing (NGS) opened up exciting possibilities for quantification of sequence mutations such that a high read depth could be enable to detect the low-level mosaic mutations. Thus, mosaicism had been increasingly reported in genes associated with epilepsy and neurodevelopmental disorders ([@B1]; [@B22]; [@B12]; [@B24]).

Here, we reported a case with two mosaic variants at the same nucleotide of the *KCNA2* gene, leading to two different pathogenic missense changes associated with epileptic encephalopathy.

Materials and Methods {#S2}
=====================

To unravel the molecular cause of the disease, trio-based exome sequencing was performed at the local genetic institutes using NGS techniques according to standards procedures. Genomic DNA was extracted from peripheral blood. NGS was performed on exon targets captured to an average target depth of 159× with over 95% of targeted regions, reaching a minimum coverage of 20×. Inheritance pattern, *in silico* predictions, control database \[including the Exome Aggregation Consortium (ExAC), Exon Mutation Sever, 1000 Genomes database, and dbSNP\], clinical laboratory reports, and findings in the literature were used to assess pathogenicity. Functional impact of mutations was predicted by three different *in silico* tools, Polyphen2^[1](#footnote1){ref-type="fn"}^, SIFT^[2](#footnote2){ref-type="fn"}^, MutationTaster^[3](#footnote3){ref-type="fn"}^, and the Varsome database^[4](#footnote4){ref-type="fn"}^. Mutations considered pathogenic or likely pathogenic were conformed via Sanger sequencing using standard methods.

For mutations in autosomal genes and X-linked genes, a mutation was considered possibly mosaic if it is observed at a lower-than-expected ratio of mutation to wild-type NGS reads and exhibited unequal amplification by Sanger sequencing. For further validated mosaic mutations in the affected patient, targeted NGS achieving a mean coverage of approximately 6950× with 100% targeted regions was performed.

We reviewed history obtained from medical records and from families via phone, including gender, age at seizure onset, seizure types, perinatal and personal history, family history, treatment and other relevant clinical data. Electroencephalogram (EEG), brain magnetic resonance and neuropsychological assessment, were reviewed.

Written informed consent was obtained from the legal guardians (parents) of the patient for diagnostic procedures and NGS. The study has been approved by the Ethical Committee of Peking University First Hospital.

Case Presentation {#S3}
=================

The patient was a 5-year-old girl. She was born at 37 weeks of gestation. During the pregnancy, her mother had a history of two risk of miscarriage treated with progesterone. She had not previously been diagnosed with infertility and had not undergone any assisted reproductive technology procedures. The patient was delivered by cesarean section with a birth weight of 2000 g. She did not require resuscitation. She was the first child of healthy non-consanguineous parents. There was no familial history of any neuropsychiatric disease including epilepsy or febrile seizures.

At the age of 18 months, she presented with a febrile generalized tonic-clonic seizure (GTCS) for about 2 min associated with herpangina. After that, she had recurrent febrile GTCS for seven times with the duration of 1--2 min and also had a fever without an attack in rare cases. At the age of 5 years and 3 months, she developed the first afebrile seizure, presenting with focal motor seizure with secondarily GTCS for about 2 min at sleep onset. She had a mildly delayed developmental milestone, especially in gross and fine motor skills. Great progress was made after effective training. Developmental regression was noticed after seizures. Now, at the age of 5 years and 11 months, there was no significant delay in gross motor and language skills. But the significant cognitive impairments were noticed, including memory problems, learning disorders, attention span and irritability. She could not complete the simple algorithm even less than ten.

No abnormality was found on the EEG at onset. At the age of 5 years and 1 month, EEG showed focal epileptiform discharges in centrotemporal area with activation during sleep ([Figure 1](#F1){ref-type="fig"}), and brain magnetic resonance imaging was normal.

![Interictal electroencephalogram demonstrating focal epileptiform discharges in centrotemporal area at the age of 5 years and 1 month.](fgene-11-00911-g001){#F1}

Rescue treatment with benzodiazepines (2.5 mg) was occasionally used by her parents when the patient had a fever and no seizure occurred. Levetiracetam treatment (33 mg/kg/d) was used at the age of 5 years and 2 months because of frequent febrile seizures and EEG abnormality. After a month, the dosage of levetiracetam was gradually increased to 50 mg/kg/d due to the first afebrile seizure. Later, because of side effects (hyperexcitability and poor sleep), the dosage of levetiracetam was reduced and valproate was added. The patient had no seizures for 8 months on combination of levetiracetam (18.75 mg/kg/d) and valproate (20 mg/kg/d) till the last follow-up at the age of 5 years and 11 months.

Trio-based whole-exome sequencing revealed two novel changes in exon 3 of the *KCNA2* gene: c.1225A \> T \[p.(Ile409Phe)\] and c.1225A \> C \[p.(Ile409Leu)\] \[NM_004974\]. Both missense mutations were in a mosaic status. NGS with a mean coverage of 159 × showed 31% (mosaic mutation reads/total reads) of the c.1225A \> T mutation and 19% of the c.1225A \> C mutation. Sanger sequencing confirmed the presence of the mutations in the patient, but not in her parents, characterizing them as *de novo* ([Figure 2A](#F2){ref-type="fig"}). Both variants were classified as likely pathogenic using ACMG criteria (see Varsome) ([@B17]; [@B11]). Further NGS data at the loci of the mutations with a mean coverage of 6950 × showed 26% of the c.1225A \> T mutation and 23% of the c.1225A \> C mutation ([Figure 2B](#F2){ref-type="fig"}).

![**(A)** The genetic map and the mutations sequence chromatograms in the *KCNA2* gene. Black circle: affected mutation-carrying female; white circle: female without *KCNA2* mutation; white square: male without *KCNA2* mutation. The red circles indicated the location of the identified mutations. **(B)** Visualization of the output bam file on Integrate Genome Viewer software tool. *KCNA2* gene region around the mutations c.1225A \> T and c.1225A \> C was analyzed with a 6950 × coverage; the sequence was shown in the forward strand. Vertical dotted lines showed the position relative to the missense mutations.](fgene-11-00911-g002){#F2}

Discussion {#S4}
==========

We firstly reported here mosaicism of a 5-year-old girl presenting with two novel missense mutations in *KCNA2*. This patient was unusual in that there were two different mosaic mutation alleles at the same nucleotide of c.1225. NGS with a mean coverage of 159 × revealed 31% of the c.1225A \> T mutation and 19% of the c.1225A \> C mutation. And NGS with higher read depth at a mean coverage of 6950 × showed 26% of the c.1225A \> T mutation and 23% the c.1225A \> C mutation.

As a recently discovered gene associated with epilepsy disorders, more than sixty cases bearing over ten different *KCNA2* mutations had been reported ([@B14]; [@B8]). The great majority of the mutations were missense and located in exon 3. Two main phenotypes emerged from the described cases ([@B19]; [@B14]). A milder phenotype associated with loss-of-function mutations comprised infantile/early childhood seizure onset, frequent febrile and afebrile focal seizures. The c.1214C \> T mutation was reported to be the most common loss-of-function mutation. A more severe phenotype carrying gain-of-function mutations presented as epilepsy, ataxia and intellectual disability. The c.1120A \> G mutation was the most common gain-of-function mutation ([@B19]). [@B14] found that some of the gain-of-function mutations also showed some additional loss-of-function effects and proposed to subgroup those patients carrying mutations with similar electrophysiological properties ([@B14]). The three phenotypic groups share some common clinical features.

Here, we report a case of *KCNA2*-related encephalopathy with two novel mutations located in a highly conserved and functionally important protein region. The mutations disrupted the pore domain of the voltage-gated potassium channel Kv1.2, which was thought to link the gate to the voltage-sensor ([@B9]; [@B13]). Both mutations were neither found in ExAC nor 1000G databases. Mosaic mutations c.1225A \> T/C \[p.(Ile409Phe/Leu)\] were both predicted as damaging by different prediction programs. Functional study of c.1214C \> T \[p.(Pro405Leu)\] found a dramatic reduction of current amplitudes and thus a clear a loss of channel function ([@B19]). Due to similar clinical and EEG characteristics, it speculated that the mutations of c.1225A \> T/C might also cause a loss-of-function effects. The sum of the allele fractions of the two mutant alleles was closed to 50%, approximately equal to heterozygous missense variants. This was consistent with the fact that *KCNA2*-related encephalopathy is an autosomal dominant disease ([@B19]). Genotype-phenotype analysis was performed. Clinically, our patient showed an age at onset in early childhood, fever sensitivity of seizures, and mild cognitive and behavioral disturbances, which were consistent with what had been previously reported in association with *KCNA2* heterozygous mutation. Taken together, mosaic mutations c.1225A \> T/C were considered to be the pathogenic cause of the disease in our patient. Furthermore, interictal EEG in patients with loss-of-function mutations, especially c.1214C \> T, had been reported to showed a peculiar pattern characterized by focal, mainly central or posterior-temporal epileptiform discharges with dramatic activation during sleep ([@B14]; [@B8]). And among the 12 reported patients with c.1214C \> T mutation, ten were presented with electrical status during sleep (ESES), diagnosed as atypical benign childhood epilepsy with centrotemporal spikes (BECT). In line with previous study, EEG in our case showed focal centrotemporal epileptiform discharges at the age of 5 years and 1 month, accompanied by nocturnal focal seizures. Therefore, our patient was more likely carrying a mutation with loss-of-function. Whether the patient would develop into atypical BECT with ESES required long-term follow-up.

Increasing evidence suggested that mosaic mutations had counted for a certain fraction of monogenic disorders, well known in tumorigenesis and overgrowth syndromes ([@B5]; [@B21]). Recently, case reports had shown mosaicism in certain epilepsy-related and neurodevelopmental genes ([@B15]; [@B12]; [@B24]). [@B18] firstly performed a systematic study of the extent and level of mosaicism detectable by NGS for patients with epilepsy ([@B18]). They indicated that mosaic pathogenic mutations were identified frequently in nine genes associated with various neurological conditions, including *CDKL5*, *GABRA1*, *GABRG2*, *GRIN2A*, *GRIN2B*, *KCNQ2*, *MECP2*, *PCDH19*, *SCN1A*, and *SCN2A*. Due to the small number of cases diagnosed with *KCNA2* gene, this was the first description of mosaicism in only one patient.

As far as we knew, only two other patients with two mutant alleles had been reported to date ([@B6]; [@B3]). [@B3] described a 4-year-old girl presenting two distinct exonic deletions of the *CDKL5* gene in a mosaic state. And they proposed to explain the co-occurrence of these two events by the Fork Stalling and Template Switching mechanism ([@B3]). In the other case with hereditary hemorrhagic telangiectasia, it involved the presence of two adjacent heterozygous deleterious mutations. Both the two mutations were located within the same hairpin structure and the author speculated a template switching model might be responsible for the abnormalities ([@B6]). In our case, we speculated that both mutations arose on the same chromosome, although the mechanism behind their formation remains unclear. The complex mosaicism might lead to underdiagnosis by routine techniques and brought a challenge to classifying pathogenicity of missense variants. In the future, the complex mosaicism in rare and genetic heterogeneous neurodevelopmental disorders should be considered in the study for new methods to interpret variant data.

The use of NGS is nowadays allowing the detection of unexpected genetic mosaicisms in genetic disease. Although we could analyze blood only, we are confident the same mosaicism was present in our patient brain, since others demonstrated that often mosaic mutations have allele frequencies similar in multiple tissues ([@B23]; [@B10]).

Conclusion {#S5}
==========

Here was the first known instance of mosaicism in the *KCNA2* gene. Our patient expanded the mutational spectrum of *KCNA2*-related encephalopathy. Moreover, the findings of this study opened a new perspective for the unusual mosaicism of two distinct mutations in *KCNA2*-related encephalopathy and provided new insight into the complex genetic disorder. It highlighted the complexity of genomic events occurring during early embryogenesis and the consequences of mutational mosaicism upon pathogenic variability.
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